EuroApi
5-year manufacturing agreement to support sales trajectory of FOCUS-27 project
The agreement highlights EUROAPI’s know-how and the reliability of its premium contract manufacturing organization services to its customers.
PARIS – May 23, 2024 – EUROAPI announced today that it has signed a Contract Manufacturing Organization (CMO) agreement with a global veterinary pharmaceutical company. As part of the collaboration, EUROAPI will supply key veterinary products to the client. The total contract value is expected to be in the range of €130 million to €150 million over the period 2025-2029.
“The signing of this major agreement ensures long-term supplies of complex chemical molecules essential for use in veterinary medicine. This is a true testament to EUROAPI’s know-how and the reliability of the premium services we offer our customers. It is a sign of recognition,” said Ludwig de Mot, CEO of EUROAPI. “This agreement will be a significant driver in the sales trajectory of our FOCUS-27 project.”
EUROAPI has strong expertise in the animal healthcare sector with a large portfolio of clients and products including hormones, prostaglandins and complex synthetic molecules. The global animal healthcare market is estimated to be worth $41.8 billion in 2023 and is expected to reach $56.8 billion by 2030, at a CAGR of 4.5%1.
About EUROAPI
EUROAPI is focused on reinventing active ingredient solutions to sustainably meet the needs of customers and patients worldwide. We are a leading active pharmaceutical ingredients player with around 200 products in our portfolio and offer a wide range of technologies whilst developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.
Taking action for health by enabling access to essential treatments is a daily motivation for our 3,650 employees. With strong R&D capabilities and six manufacturing sites all located in Europe, EUROAPI guarantees the highest quality API production for customers in more than 80 countries. EUROAPI is listed on Euronext Paris (ISIN: FR0014008VX5, ticker: EAPI). For more information, visit www.euroapi.com and follow us on LinkedIn.
Forward-Looking Statements
Certain information contained in this press release is forward-looking and not historical data. These forward-looking statements are based on opinions, projections and current assumptions. These include, but are not limited to, assumptions regarding the Group's current and future strategy, future financial and non-financial results, the environment in which the Group operates, as well as events, operations, the development and potential of future services or products. Forward-looking statements are typically identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Forward-looking statements and information are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, many of which are difficult to predict and generally beyond the Group's control, which may cause actual results, performance or achievements, or the outcome of sectors or other events, to differ materially from those described or implied in these forward-looking statements. These risks and uncertainties include those set out and further described in Chapter 3 “Risk Factors” of the Universal Registration Document filed with the French Financial Market Supervisory Authority (Autorité des marchés financiers, AMF) on April 5, 2024. These forward-looking statements are presented only as of the date of this press release and the Group expressly disclaims any obligation or undertaking to publicly update or correct any forward-looking statements contained in this press release to reflect any changes affecting its expectations or events, conditions or circumstances on which these forward-looking statements are based.
The story continues
1 Source: https://healthforanimals.org/ and company estimates.
attachment
